BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zeng C, Zhang C, Walker PG, Dong Y. Formulation and Delivery Technologies for mRNA Vaccines. Curr Top Microbiol Immunol 2020. [PMID: 32483657 DOI: 10.1007/82_2020_217] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
Number Citing Articles
1 Khoshnood S, Ghanavati R, Shirani M, Ghahramanpour H, Sholeh M, Shariati A, Sadeghifard N, Heidary M. Viral vector and nucleic acid vaccines against COVID-19: A narrative review. Front Microbiol 2022;13:984536. [DOI: 10.3389/fmicb.2022.984536] [Reference Citation Analysis]
2 Ura T, Takeuchi M, Kawagoe T, Mizuki N, Okuda K, Shimada M. Current Vaccine Platforms in Enhancing T-Cell Response. Vaccines (Basel) 2022;10:1367. [PMID: 36016254 DOI: 10.3390/vaccines10081367] [Reference Citation Analysis]
3 Nitika, Wei J, Hui AM. The Delivery of mRNA Vaccines for Therapeutics. Life (Basel) 2022;12:1254. [PMID: 36013433 DOI: 10.3390/life12081254] [Reference Citation Analysis]
4 Gebre MS, Rauch S, Roth N, Gergen J, Yu J, Liu X, Cole AC, Mueller SO, Petsch B, Barouch DH. mRNA vaccines induce rapid antibody responses in mice. NPJ Vaccines 2022;7:88. [PMID: 35915094 DOI: 10.1038/s41541-022-00511-y] [Reference Citation Analysis]
5 Oluwagbemi OO, Oladipo EK, Kolawole OM, Oloke JK, Adelusi TI, Irewolede BA, Dairo EO, Ayeni AE, Kolapo KT, Akindiya OE, Ayobami OJ, Oluwadara BF, Fatumo S. Bioinformatics, Computational Informatics, and Modeling Approaches to the Design of mRNA COVID-19 Vaccine Candidates. Computation 2022;10:117. [DOI: 10.3390/computation10070117] [Reference Citation Analysis]
6 Chen H, Ren X, Xu S, Zhang D, Han T. Optimization of Lipid Nanoformulations for Effective mRNA Delivery. IJN 2022;Volume 17:2893-905. [DOI: 10.2147/ijn.s363990] [Reference Citation Analysis]
7 Duan LJ, Wang Q, Zhang C, Yang DX, Zhang XY. Potentialities and Challenges of mRNA Vaccine in Cancer Immunotherapy. Front Immunol 2022;13:923647. [PMID: 35711457 DOI: 10.3389/fimmu.2022.923647] [Reference Citation Analysis]
8 Wei J, Hui A. The Paradigm Shift in Treatment from Covid-19 to Oncology with mRNA Vaccines. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102405] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Rouf NZ, Biswas S, Tarannum N, Oishee LM, Muna MM. Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases. RNA Biol 2022;19:386-410. [PMID: 35354425 DOI: 10.1080/15476286.2022.2055923] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Fang E, Liu X, Li M, Zhang Z, Song L, Zhu B, Wu X, Liu J, Zhao D, Li Y. Advances in COVID-19 mRNA vaccine development. Signal Transduct Target Ther 2022;7:94. [PMID: 35322018 DOI: 10.1038/s41392-022-00950-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
11 Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol 2022;15:28. [PMID: 35303904 DOI: 10.1186/s13045-022-01247-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
12 Aliahmad P, Miyake-Stoner SJ, Geall AJ, Wang NS. Next generation self-replicating RNA vectors for vaccines and immunotherapies. Cancer Gene Ther 2022. [PMID: 35194198 DOI: 10.1038/s41417-022-00435-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Molehin AJ, McManus DP, You H. Vaccines for Human Schistosomiasis: Recent Progress, New Developments and Future Prospects. Int J Mol Sci 2022;23:2255. [PMID: 35216369 DOI: 10.3390/ijms23042255] [Reference Citation Analysis]
14 Le T, Sun C, Chang J, Zhang G, Yin X. mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases. Viruses 2022;14:401. [DOI: 10.3390/v14020401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Hallam J, Jones T, Alley J, Kohut ML. Exercise after influenza or COVID-19 vaccination increases serum antibody without an increase in side effects. Brain Behav Immun 2022;102:1-10. [PMID: 35131444 DOI: 10.1016/j.bbi.2022.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Jin Y, Hou C, Li Y, Zheng K, Wang C. mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2. Front Immunol 2022;12:821538. [DOI: 10.3389/fimmu.2021.821538] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
17 Rajendran AK, Amirthalingam S, Hwang NS. A brief review of mRNA therapeutics and delivery for bone tissue engineering. RSC Adv 2022;12:8889-900. [DOI: 10.1039/d2ra00713d] [Reference Citation Analysis]
18 Rahimnejad M, Rabiee N, Ahmadi S, Jahangiri S, Sajadi SM, Akhavan O, Saeb MR, Kwon W, Kim M, Hahn SK. Emerging Phospholipid Nanobiomaterials for Biomedical Applications to Lab-on-a-Chip, Drug Delivery, and Cellular Engineering. ACS Appl Bio Mater 2021;4:8110-28. [PMID: 35005915 DOI: 10.1021/acsabm.1c00932] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
19 Exner RM, Paisey SJ, Redman JE, Pascu SI. Explorations into Peptide Nucleic Acid Contrast Agents as Emerging Scaffolds for Breakthrough Solutions in Medical Imaging and Diagnosis. ACS Omega 2021;6:28455-62. [PMID: 34746541 DOI: 10.1021/acsomega.1c03994] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Constantin C, Pisani A, Bardi G, Neagu M. Nano-carriers of COVID-19 vaccines: the main pillars of efficacy. Nanomedicine (Lond) 2021;16:2377-87. [PMID: 34632802 DOI: 10.2217/nnm-2021-0250] [Reference Citation Analysis]
21 Held J, Esse J, Tascilar K, Steininger P, Schober K, Irrgang P, Alsalameh R, Tenbusch M, Seggewies C, Bogdan C. Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty®). Vaccines (Basel) 2021;9:1063. [PMID: 34696171 DOI: 10.3390/vaccines9101063] [Reference Citation Analysis]
22 Naderi Sohi A, Kiani J, Arefian E, Khosrojerdi A, Fekrirad Z, Ghaemi S, Zim MK, Jalili A, Bostanshirin N, Soleimani M. Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque. Vaccines (Basel) 2021;9:1007. [PMID: 34579244 DOI: 10.3390/vaccines9091007] [Reference Citation Analysis]
23 Celis-Giraldo CT, López-Abán J, Muro A, Patarroyo MA, Manzano-Román R. Nanovaccines against Animal Pathogens: The Latest Findings. Vaccines (Basel) 2021;9:988. [PMID: 34579225 DOI: 10.3390/vaccines9090988] [Reference Citation Analysis]
24 Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines 2021;6:104. [PMID: 34400651 DOI: 10.1038/s41541-021-00369-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
25 Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater 2021;:1-17. [PMID: 34394960 DOI: 10.1038/s41578-021-00358-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 220] [Article Influence: 2.0] [Reference Citation Analysis]
26 Gao Y, Yang K, Shelling AN, Wu Z. Nanotechnology-Enabled COVID-19 mRNA Vaccines. Encyclopedia 2021;1:773-80. [DOI: 10.3390/encyclopedia1030059] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Lucchese G, Jahantigh HR, De Benedictis L, Lovreglio P, Stufano A. An Epitope Platform for Safe and Effective HTLV-1-Immunization: Potential Applications for mRNA and Peptide-Based Vaccines. Viruses 2021;13:1461. [PMID: 34452327 DOI: 10.3390/v13081461] [Reference Citation Analysis]
28 Chakraborty C, Sharma AR, Bhattacharya M, Lee SS. From COVID-19 to Cancer mRNA Vaccines: Moving From Bench to Clinic in the Vaccine Landscape. Front Immunol 2021;12:679344. [PMID: 34305909 DOI: 10.3389/fimmu.2021.679344] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
29 Cappellano G, Abreu H, Casale C, Dianzani U, Chiocchetti A. Nano-Microparticle Platforms in Developing Next-Generation Vaccines. Vaccines (Basel) 2021;9:606. [PMID: 34198865 DOI: 10.3390/vaccines9060606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Talotta R, Robertson ES. Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that breaks the camel's back? Cytokine Growth Factor Rev 2021;60:52-60. [PMID: 34090785 DOI: 10.1016/j.cytogfr.2021.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Raoufi E, Bahramimeimandi B, Salehi-Shadkami M, Chaosri P, Mozafari MR. Methodical Design of Viral Vaccines Based on Avant-Garde Nanocarriers: A Multi-Domain Narrative Review. Biomedicines 2021;9:520. [PMID: 34066608 DOI: 10.3390/biomedicines9050520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Beck JD, Reidenbach D, Salomon N, Sahin U, Türeci Ö, Vormehr M, Kranz LM. mRNA therapeutics in cancer immunotherapy. Mol Cancer 2021;20:69. [PMID: 33858437 DOI: 10.1186/s12943-021-01348-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 36] [Article Influence: 2.0] [Reference Citation Analysis]
33 Kowalzik F, Schreiner D, Jensen C, Teschner D, Gehring S, Zepp F. mRNA-Based Vaccines. Vaccines (Basel) 2021;9:390. [PMID: 33921028 DOI: 10.3390/vaccines9040390] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
34 Danese E, Montagnana M, Salvagno GL, Peserico D, Pighi L, De Nitto S, Henry BM, Porru S, Lippi G. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series. Clin Chem Lab Med 2021;59:1585-91. [PMID: 33838087 DOI: 10.1515/cclm-2021-0339] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
35 Park JW, Lagniton PNP, Liu Y, Xu RH. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci 2021;17:1446-60. [PMID: 33907508 DOI: 10.7150/ijbs.59233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 54] [Article Influence: 2.0] [Reference Citation Analysis]
36 Ho W, Gao M, Li F, Li Z, Zhang XQ, Xu X. Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery. Adv Healthc Mater 2021;10:e2001812. [PMID: 33458958 DOI: 10.1002/adhm.202001812] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 46.0] [Reference Citation Analysis]
37 Borah P, Deb PK, Al-Shar'i NA, Dahabiyeh LA, Venugopala KN, Singh V, Shinu P, Hussain S, Deka S, Chandrasekaran B, Jaradat DMM. Perspectives on RNA Vaccine Candidates for COVID-19. Front Mol Biosci 2021;8:635245. [PMID: 33869282 DOI: 10.3389/fmolb.2021.635245] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
38 Rosa SS, Prazeres DMF, Azevedo AM, Marques MPC. mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine 2021;39:2190-200. [PMID: 33771389 DOI: 10.1016/j.vaccine.2021.03.038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
39 Sagili Anthony DP, Sivakumar K, Venugopal P, Sriram DK, George M. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges. Clin Drug Investig 2021;41:499-509. [PMID: 33754328 DOI: 10.1007/s40261-021-01022-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Heinz FX, Stiasny K. Profiles of current COVID-19 vaccines. Wien Klin Wochenschr 2021;133:271-83. [PMID: 33725201 DOI: 10.1007/s00508-021-01835-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
41 Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer 2021;20:41. [PMID: 33632261 DOI: 10.1186/s12943-021-01335-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 101] [Article Influence: 14.0] [Reference Citation Analysis]
42 Legere RM, Cohen ND, Poveda C, Bray JM, Barhoumi R, Szule JA, de la Concha-Bermejillo A, Bordin AI, Pollet J. Safe and effective aerosolization of in vitro transcribed mRNA to the respiratory tract epithelium of horses without a transfection agent. Sci Rep 2021;11:371. [PMID: 33432084 DOI: 10.1038/s41598-020-79855-1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
43 Russell RL, Pelka P, Mark BL. Frontrunners in the race to develop a SARS-CoV-2 vaccine. Can J Microbiol 2021;67:189-212. [PMID: 33264067 DOI: 10.1139/cjm-2020-0465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Zafar S, Arshad MS, Fatima S, Ali A, Zaman A, Sayed E, Chang MW, Ahmad Z. COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics. Pharmaceutics 2020;12:E945. [PMID: 33023033 DOI: 10.3390/pharmaceutics12100945] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
45 Liu Y, Liu Z, Cui W, Li Y, Qin X, Zhang M, Lin Y. Tetrahedral framework nucleic acids as an advanced drug delivery system for oligonucleotide drugs. APL Materials 2020;8:100701. [DOI: 10.1063/5.0025211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 [DOI: 10.1101/2020.09.03.280446] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Reference Citation Analysis]